| 2016-12-01 09:51:09|
TXMD 09:51 12/01 12/01/16
TherapeuticsMD uniquely positioned for 'clean label' for Yuvvexy, says Jefferies
Jefferies analyst Matthew Andrews noted that the Congressional Caucus for Women's Issues has urged the FDA to reconsider labeling of low-dose vaginal estrogen therapy for vulvovaginal atrophy and that the FDA is "clearly committed" to potentially amend their labels. A label without the warnings would be a "game-changer" for TherapeuticsMD's Yuvvexy, expanding its market to 32M women from 8M, and the drug is uniquely positioned to potentially be the first to receive such a "clean label," said Andrews, who keeps a Buy rating on the stock.